Attached files
| file | filename |
|---|---|
| 8-K - ZIOPHARM ONCOLOGY INC | v210073_8k.htm |
| EX-5.1 - ZIOPHARM ONCOLOGY INC | v210073_ex5-1.htm |
| EX-1.1 - ZIOPHARM ONCOLOGY INC | v210073_ex1-1.htm |
Exhibit
99.1
ZIOPHARM
PRICES PUBLIC OFFERING OF COMMON STOCK
NEW YORK, NY – February 3,
2011 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing
of an underwritten public offering of 9,600,000 shares of its common stock at a
price to the public of $5.75 per share. The public offering is expected to close
on or about February 8, 2011, subject to customary closing conditions. In
addition, ZIOPHARM Oncology has granted the underwriter a 30-day option to
purchase up to 1,440,000 additional shares of common stock to cover
overallotments.
Barclays
Capital Inc. is acting as sole book-running manager in this
offering.
The
securities described above are being offered by ZIOPHARM pursuant to a shelf
registration statement previously filed with and declared effective by the
Securities and Exchange Commission (the “SEC”) on May 13, 2010. Copies of the
prospectus supplement and related prospectus, when available, may be obtained
from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone:
888-603-5847).
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of, the shares in any state or other
jurisdiction which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or
other jurisdiction.
About
ZIOPHARM Oncology, Inc.
ZIOPHARM
Oncology is a biopharmaceutical company engaged in the development and
commercialization of a diverse portfolio of cancer therapeutics. The Company is
currently focused on several clinical programs. Palifosfamide (ZymafosTM or
ZIO-201) references a novel composition (tris formulation) that is the
functional active metabolite of ifosfamide, a standard of care for treating
sarcoma and other cancers. Darinaparsin (ZinaparTM or
ZIO-101) is a novel organic arsenic being developed for the treatment of various
hematologic and solid cancers. Indibulin (ZybulinTM or
ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and
cancer cell migration. ZIOPHARM is also pursuing the development of novel
DNA-based biotherapeutics in the field of cancer pursuant to a partnering
arrangement with Intrexon Corporation. The partnership includes a clinical-stage
product candidate in a Phase Ib study and a second product candidate that is the
basis of an Investigational New Drug application that ZIOPHARM expects to submit
during the first half of 2011.
ZIOPHARM’s
operations are located in Boston, MA with an executive office in New
York.
Forward-Looking
Safe Harbor Statement
This
press release contains forward-looking statements, including statements related
to ZIOPHARM Oncology's public offering of common stock and the completion of the
offering that involve risks and uncertainties. These forward-looking statements
are based upon ZIOPHARM Oncology's current expectations. Actual results and the
timing of events could differ materially from those anticipated in such
forward-looking statements as a result of risks and uncertainties, which
include, without limitation, risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions related to the
proposed offering and other risks detailed in ZIOPHARM Oncology's filings with
the SEC. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and ZIOPHARM Oncology undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances after the date
of this press release.
# # #
Contact:
Tyler
Cook
ZIOPHARM
Oncology, Inc.
617-259-1982
tcook@ziopharm.com